Clinical Trial Update: A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) [Phase 2]

View source ↗

Summary

This is a Phase 2 trial comparing Balversa (erdafitinib) to investigator-choice intravesical chemotherapy in patients with high-risk non-muscle-invasive bladder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Urinary Bladder Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2025-08-01